CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Nandita Vijayasimha, Bengaluru Thursday, February 6, 2025, 08:00 Hrs [IST] ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

New licensing rules mandate compliance with Schedule TB for ASU nasal sprays for patient safety: Shardul Nautiyal, Mumbai Friday, January 24, 2025, 08:00 Hrs [IST] The Union minis ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...